Index RUT
P/E -
EPS (ttm) -2.19
Insider Own 7.51%
Shs Outstand 62.07M
Perf Week 15.32%
Market Cap 259.66M
Forward P/E -
EPS next Y -2.06
Insider Trans 0.00%
Shs Float 58.01M
Perf Month 14.68%
Income -136.37M
PEG -
EPS next Q 0.21
Inst Own 92.44%
Short Float 9.53%
Perf Quarter -14.29%
Sales 41.02M
P/S 6.33
EPS this Y -1235.52%
Inst Trans -7.33%
Short Ratio 6.69
Perf Half Y -76.40%
Book/sh 0.92
P/B 4.49
EPS next Y -2.97%
ROA -53.82%
Short Interest 5.53M
Perf Year -18.50%
Cash/sh 2.24
P/C 1.85
EPS next 5Y -
ROE -118.91%
52W Range 2.95 - 21.88
Perf YTD -56.96%
Dividend Est. -
P/FCF -
EPS past 5Y 48.88%
ROI -155.91%
52W High -81.08%
Beta 2.09
Dividend TTM -
Quick Ratio 2.69
Sales past 5Y 15.77%
Gross Margin 61.08%
52W Low 40.29%
ATR (14) 0.21
Dividend Ex-Date -
Current Ratio 2.71
EPS Y/Y TTM -1959.74%
Oper. Margin -479.76%
RSI (14) 71.73
Volatility 5.81% 5.69%
Employees 339
Debt/Eq 0.59
Sales Y/Y TTM -73.10%
Profit Margin -332.47%
Recom 2.18
Target Price 7.71
Option/Short Yes / Yes
LT Debt/Eq 0.51
EPS Q/Q -196.24%
Payout -
Rel Volume 1.04
Prev Close 3.74
Sales Surprise -48.43%
EPS Surprise -34.66%
Sales Q/Q -17.81%
Earnings Aug 06 AMC
Avg Volume 826.10K
Price 4.14
SMA20 21.36%
SMA50 19.99%
SMA200 -55.17%
Trades
Volume 860,315
Change 10.70%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-01-24 Downgrade
BTIG Research
Buy → Neutral
Jul-31-24 Downgrade
Guggenheim
Buy → Neutral
Jul-31-24 Downgrade
B. Riley Securities
Buy → Neutral
$18 → $5
May-10-24 Downgrade
TD Cowen
Buy → Hold
May-10-24 Downgrade
Stifel
Buy → Hold
$29 → $7
May-10-24 Downgrade
BMO Capital Markets
Outperform → Market Perform
$24 → $8
Apr-26-24 Initiated
B. Riley Securities
Buy
$25
Apr-09-24 Upgrade
TD Cowen
Hold → Buy
Mar-04-24 Reiterated
BTIG Research
Buy
$12 → $24
Feb-14-24 Downgrade
H.C. Wainwright
Buy → Neutral
$12 → $14
Dec-20-23 Upgrade
Citigroup
Neutral → Buy
$7 → $13
Nov-07-23 Upgrade
Guggenheim
Neutral → Buy
$12
Mar-17-23 Downgrade
Guggenheim
Buy → Neutral
Nov-22-22 Downgrade
Cowen
Outperform → Market Perform
Nov-14-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$5.70 → $16
Jul-18-22 Downgrade
SMBC Nikko
Outperform → Neutral
$5
Jul-11-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$31 → $4
May-04-22 Downgrade
Guggenheim
Buy → Neutral
Feb-28-22 Upgrade
Citigroup
Neutral → Buy
$23 → $21
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$31
Show Previous Ratings
Sep-24-24 05:45AM
Sep-23-24 11:05AM
Sep-20-24 05:06AM
Sep-19-24 01:29PM
Sep-17-24 08:30AM
05:45AM
Loading…
05:45AM
Sep-15-24 03:00AM
Sep-13-24 08:34AM
Sep-11-24 08:30AM
Sep-08-24 07:10PM
Sep-04-24 03:29PM
Sep-03-24 05:45AM
Sep-02-24 02:05PM
Aug-30-24 09:43AM
Aug-29-24 01:09PM
10:48AM
Loading…
Aug-27-24 10:48AM
Aug-26-24 03:40PM
Aug-22-24 03:16PM
01:17PM
Aug-21-24 07:05AM
Aug-19-24 04:37PM
Aug-17-24 03:29PM
Aug-16-24 05:45AM
04:26AM
Aug-15-24 02:19PM
Aug-14-24 12:19PM
Aug-13-24 02:31PM
12:45AM
Aug-12-24 10:20AM
Aug-08-24 11:31AM
08:53AM
Loading…
Aug-07-24 08:53AM
Aug-06-24 09:30PM
05:30PM
04:33PM
(Associated Press Finance)
04:01PM
Jul-30-24 04:10PM
04:01PM
Jul-24-24 01:29PM
Jul-16-24 03:57PM
Jul-10-24 05:19PM
Jul-03-24 05:34PM
Jun-20-24 01:28PM
Jun-13-24 12:29PM
Jun-11-24 07:45AM
May-29-24 12:44PM
May-25-24 12:00PM
May-17-24 12:50PM
May-16-24 12:59PM
May-13-24 12:30PM
07:30AM
May-10-24 06:01PM
04:51PM
(The Wall Street Journal)
03:29PM
03:17PM
02:01PM
08:35AM
07:48AM
07:30AM
07:15AM
07:14AM
07:12AM
07:12AM
06:02AM
04:57AM
02:15AM
May-09-24 08:57PM
04:10PM
(Associated Press Finance)
04:01PM
May-03-24 07:30AM
May-01-24 10:05AM
Apr-26-24 08:00AM
Apr-03-24 04:30PM
Mar-14-24 08:18AM
Mar-09-24 01:09PM
Mar-08-24 07:19AM
(Thomson Reuters StreetEvents) -15.02%
12:30AM
Mar-07-24 10:42PM
09:55PM
05:30PM
04:01PM
Mar-06-24 11:29PM
Mar-01-24 05:48PM
(GlobeNewswire) +6.24%
+8.71%
Feb-29-24 10:00AM
Feb-27-24 05:45PM
Feb-02-24 04:30PM
07:19AM
Jan-15-24 04:51PM
Jan-08-24 04:30PM
Dec-17-23 12:03PM
Nov-07-23 10:56AM
(Thomson Reuters StreetEvents) +17.10%
08:59AM
01:15AM
Nov-06-23 05:12PM
04:27PM
(Associated Press Finance)
04:01PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Sep-05-23 07:00AM
Aug-31-23 04:30PM
Aug-19-23 07:40AM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SIEGEL JAY PHILIP Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:34 PM HEIDEN WILLIAM K Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:34 PM Jackson Scott Thomas Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:34 PM STUMP DAVID C Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:33 PM O'Brien Federica F. Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:33 PM Liu Margaret Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:33 PM Chhabra Meenu Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:33 PM Ferrante Karen Jean Director May 20 '24 Option Exercise 0.00 4,500 0 4,500 May 22 04:32 PM HURWITZ EDWARD Director May 20 '24 Option Exercise 0.00 4,500 0 37,574 May 22 04:32 PM Peters Jeffrey Stuart Senior VP and General Counsel Apr 04 '24 Option Exercise 4.82 42,500 204,850 51,395 Apr 08 06:07 PM Peters Jeffrey Stuart Senior VP and General Counsel Apr 04 '24 Sale 15.55 51,395 799,148 0 Apr 08 06:07 PM Peters Jeffrey Stuart Senior VP and General Counsel Mar 06 '24 Option Exercise 10.90 19,625 213,875 28,520 Mar 08 04:14 PM Peters Jeffrey Stuart Senior VP and General Counsel Mar 06 '24 Sale 21.50 19,625 421,938 8,895 Mar 08 04:14 PM Risser Eric Blasius Chief Operating Officer Mar 04 '24 Option Exercise 10.15 15,000 152,250 80,059 Mar 06 04:20 PM Risser Eric Blasius Chief Operating Officer Mar 04 '24 Sale 19.76 41,159 813,501 38,900 Mar 06 04:20 PM Spitznagel Thomas Sr VP, Technical Ops Mar 04 '24 Option Exercise 11.50 10,000 115,000 18,316 Mar 06 04:19 PM Spitznagel Thomas Sr VP, Technical Ops Mar 04 '24 Sale 20.00 10,000 200,000 8,316 Mar 06 04:19 PM Karrels James SVP, CFO and Secretary Mar 04 '24 Sale 20.50 30,000 615,000 171,452 Mar 06 04:18 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 26 '24 Sale 17.22 16,124 277,655 8,895 Feb 28 04:20 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 22 '24 Option Exercise 0.00 26,250 0 35,145 Feb 26 04:27 PM Bonvini Ezio Sr VP, Research & CSO Feb 22 '24 Option Exercise 0.00 28,125 0 110,258 Feb 26 04:26 PM Eck Stephen L. Chief Medical Officer Feb 15 '24 Option Exercise 0.00 16,670 0 16,670 Feb 20 06:41 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 15 '24 Option Exercise 0.00 13,336 0 13,336 Feb 20 06:05 PM Koenig Scott President and CEO Feb 15 '24 Option Exercise 0.00 42,341 0 1,091,977 Feb 20 06:04 PM Cilinski Lynn VP, Controller and Treasurer Feb 15 '24 Option Exercise 0.00 6,668 0 8,591 Feb 20 06:04 PM Risser Eric Blasius Chief Operating Officer Feb 15 '24 Option Exercise 0.00 16,670 0 70,938 Feb 20 06:04 PM Karrels James SVP, CFO and Secretary Feb 15 '24 Option Exercise 0.00 15,003 0 206,779 Feb 20 06:04 PM Spitznagel Thomas Sr VP, Technical Ops Feb 15 '24 Option Exercise 0.00 13,336 0 13,336 Feb 20 06:03 PM Bonvini Ezio Sr VP, Research & CSO Feb 15 '24 Option Exercise 0.00 16,670 0 88,004 Feb 20 06:03 PM Bonvini Ezio Sr VP, Research & CSO Feb 07 '24 Sale 18.00 3,334 60,012 71,334 Feb 07 04:19 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 05 '24 Option Exercise 11.11 76,251 847,355 76,251 Feb 07 04:17 PM Peters Jeffrey Stuart Senior VP and General Counsel Feb 05 '24 Sale 16.50 76,251 1,258,142 0 Feb 07 04:17 PM Bonvini Ezio Sr VP, Research & CSO Feb 01 '24 Sale 15.00 13,316 199,740 74,668 Feb 02 04:21 PM Bonvini Ezio Sr VP, Research & CSO Jan 19 '24 Sale 12.00 13,316 159,792 87,984 Jan 22 04:57 PM Bonvini Ezio Sr VP, Research & CSO Dec 20 '23 Sale 10.08 18,880 190,310 101,300 Dec 21 04:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite